Psoriatic arthritis clinical trials

Explore recruiting psoriatic arthritis clinical trials.

Recruiting psoriatic arthritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psoriatic arthritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Germany, Belgium, Spain, Czechia, Croatia, Portugal +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

Spain, Germany, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm, to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors

Spain, Czechia, Bulgaria, Poland, Hungary, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, RISANKIZUMABCONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT STUDY PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS

Germany, Poland, Bulgaria, Spain, Hungary, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Italy, Czechia, Belgium, Croatia, Portugal, Germany +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Psoriatic arthritis trials by city

Psoriatic arthritis in Toronto Psoriatic arthritis in Vancouver Psoriatic arthritis in Montreal Psoriatic arthritis in Calgary Psoriatic arthritis in Edmonton Psoriatic arthritis in Ottawa Psoriatic arthritis in Winnipeg Psoriatic arthritis in Quebec City Psoriatic arthritis in Hamilton Psoriatic arthritis in Kitchener Psoriatic arthritis in London Psoriatic arthritis in Halifax Psoriatic arthritis in New York Psoriatic arthritis in Los Angeles Psoriatic arthritis in Chicago Psoriatic arthritis in Houston

Other conditions

Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Irritable bowel syndrome Celiac disease GERD Eosinophilic esophagitis Gastroparesis Rheumatoid arthritis Lupus Ankylosing spondylitis Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome Scleroderma Fibromyalgia Psoriasis Eczema (atopic dermatitis) Acne Vitiligo Hidradenitis suppurativa